We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 1,832

Africa update - November 6, 2014
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • Africa, European Union, Global, USA
  • November 6 2014

On October 29th, the U.S. Agency for International Development (USAID) issued a new fact sheet on the Ebola outbreak. The fact sheet highlighted the

Global intellectual property newsletter - issue 0115
  • Clifford Chance LLP
  • China, European Union, Germany, Poland, Spain, United Kingdom, USA
  • January 21 2015

Establishment of the Unified European Patent Litigation System has been subject to many efforts of European leaders and legislators for more than four

Network interference - a legal guide to the commercial risks and rewards of the social media phenomenon
  • Reed Smith LLP
  • European Union, Global, United Kingdom, USA
  • April 22 2014

Social media is a revolution in the way in which corporations communicate with consumers. This White Paper will help you to maximise the huge

US and European approaches to antibody patents
  • FB Rice
  • European Union, USA
  • June 13 2013

When monoclonal antibodies were first produced in 1974, Kohler and Milstein predicted that they “could be valuable for medical and industrial use”

Dispelling the Myriad gene patent harmonization myth
  • Foley & Lardner LLP
  • Australia, Canada, European Union, France, Germany, Japan, USA
  • April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

Life sciences: 2013 legal developments you need to know about
  • Mayer Brown LLP
  • China, European Union, France, USA
  • July 16 2013

This is a short guide outlining some of the key legal developments in the life sciences sector in 2013. The developments include the Supreme Court

Sunshine in Europe for pharmaceutical companies?
  • Hunton & Williams LLP
  • European Union, USA
  • July 11 2013

On June 24th, the European Federation of Pharmaceutical Industries and Associations (EFPIA) adopted a "Disclosure code of transfers of value to

NNCO to schedule nanotech-related meetings in collaboration with EC
  • Shook Hardy & Bacon LLP
  • European Union, USA
  • September 19 2014

The National Nanotechnology Coordination Office (NNCO) is joining with the European Commission over the next year to host meetings for the six U.S

Outside of FDA
  • Drinker Biddle & Reath LLP
  • European Union, Global, United Kingdom, USA
  • June 30 2008

The European Directorate for the Quality of Medicines & HealthCare (EDQM, Council of Europe), recently met with the Ministry of Health of India and the Indian Pharmacopoeia Commission (IPC) to discuss improving the quality and safety of medicines in both locations, and developing joint inspections of DBR Reg Sci May - June 2008 Page 7 manufacturing sites

Canada: transparency of dealings between pharmaceutical companies and healthcare professionals
  • Norton Rose Fulbright LLP
  • Canada, European Union, France, USA
  • October 30 2013

Several countries have recently introduced legislation andor industry codes promoting the transparency of payments by pharmaceutical manufacturers